Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
6114043 | Transfusion and Apheresis Science | 2015 | 4 Pages |
Abstract
Rh alloimmunization remains a potentially devastating complication of pregnancy, with fetal anemia causing hydrops and intrauterine death. Intrauterine transfusion is the standard treatment, but is particularly dangerous before 20 weeks gestation. When the need for intrauterine transfusion is anticipated early in pregnancy, immune-modulating therapies such as plasmapheresis and IVIG have been used to delay transfusion to a later gestational age. We report a 35-year-old G5P1 Rh(D)-negative woman with severe Rh alloimmunization managed successfully with sequential plasmapheresis, intravenous immune globulin and intrauterine transfusion. The optimal plasmapheresis treatment protocol and incremental benefit of IVIG remains unknown.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Hematology
Authors
Brett L. Houston, Rachelle Govia, Ahmed M. Abou-Setta, Gregory J. Reid, Marie Hadfield, Chantalle Menard, Jocelyn Noyd, Susan Main, Ryan Zarychanski,